CERS


Cantor Weighs In on Cerus Corporation (CERS) as FDA Halted Blood Donations in Two FL Counties Due to Zika

Cantor analyst Bryan Brokmeier reiterated a Buy rating on shares of Cerus Corporation (NASDAQ:CERS), with a $9.00 price target, after the FDA announced that it is requesting that …

Cantor Assumes Buy on Cerus Corporation (CERS), Sees 40% Upside for the Stock

In a research report sent to investors Thursday, Cantor analyst Bryan Brokmeier assumed coverage on shares of Cerus Corporation (NASDAQ:CERS), with a Buy rating and price …

Baird Bullish on EXACT Sciences Corporation (EXAS) and Cerus Corporation (CERS); Here’s Why

Analyst Catherine Ramsey of Robert W. Baird is bullish on EXACT Sciences Corporation (NASDAQ:EXAS) and Cerus Corporation (NASDAQ:CERS) following positive developments surrounding their products.

Analysts Reiterate Buy on Cerus Corporation (CERS) and Ariad Pharmaceuticals, Inc. (ARIA) Following Agreement with BARDA and Analyst Day

Pipeline updates from biotech companies Cerus Corporation (NASDAQ:CERS) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) cause analysts to reiterate Buy ratings on both, highlighting various …

FBR Maintains Positive Outlook on Peregrine Pharmaceuticals (PPHM) and Cerus Corporation (CERS) Due to Promising Developments

Analyst Thomas Yip of FBR & Co is Bullish on biotech companies Peregrine Pharmaceuticals (NASDAQ:PPHM) and Cerus Corporation (NASDAQ:CERS). The analyst remains positive …

The Ups and Downs of Biotech: Cerus Corporation (CERS) and BioCryst Pharmaceuticals, Inc. (BCRX)

The volatile biotech sector did not fail to live up to its reputation this week. Analysts weigh in on Cerus Corporation (NASDAQ:CERS) as …

Company Update (NASDAQ:CERS): Cerus Corporation and Unyts Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma

Cerus Corporation (NASDAQ:CERS) announced that Unyts has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Unyts provides blood …

Company Update (NASDAQ:CERS): Cerus Corporation and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma

Cerus Corporation (NASDAQ:CERS) announced that Bonfils Blood Center has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Bonfils …

Company Update (NASDAQ:CERS): Cerus Corporation Announces First INTERCEPT Pathogen Reduced Platelet Units Produced in the Continental US

Cerus Corporation (NASDAQ:CERS) and the SunCoast Blood Bank announced that the first pathogen reduced platelet units have been produced in the continental US. This …

Stock Update (NASDAQ:CERS): Richard J. Benjamin, MD PhD Appointed as Cerus Corporation’s New Chief Medical Officer

Cerus Corporation (NASDAQ:CERS) announced that Richard J. Benjamin, MD PhD has been appointed as chief medical officer of Cerus, effective July 13, 2015.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts